AIMS: Ablation of frequent premature ventricular complexes (PVCs) improves left ventricular ejection fraction in patients with left ventricular (LV) systolic dysfunction. This study aims to evaluate the long-term hard outcomes and potential prognostic variables in this population. METHODS AND RESULTS: Prospective multicentre study including 101 consecutive patients [56 ± 12 years old, 62 (61%) men] with LV systolic dysfunction and frequent PVCs who underwent PVC ablation before November 2015. The last evaluation performed was considered the long-term follow-up (LTFUP) evaluation. Mean follow-up was 34 ± 16 months (range 24-84 months). Ablation was successful in 95 (94%) patients. There was a significant reduction in the PVC burden from 21 ± 12% at baseline to 3.8 ± 6% at LTFUP, P < 0.001. Left ventricular ejection fraction improved from 32 ± 8% at baseline to 39 ± 12% at LTFUP (P < 0.001) and New York Heart Association class from 2.2 ± 0.6% to 1.3 ± 0.6% (P < 0.001). Brain natriuretic peptide levels decreased from 136 (78-321) to 68 (32-144) pg/mL (P = 0.007). Most of this improvement occurs during the first 6 months after ablation. Persistent abolition of at least 18 points of the baseline PVC burden was independently and inversely associated with the composite endpoint of cardiac mortality, cardiac transplantation, or hospitalization for heart failure during follow-up [hazard ratio 0.18 (0.05-0.66), P = 0.01]. CONCLUSION: In patients with LV systolic dysfunction, ablation of frequent PVCs induces a significant improvement in functional, structural, and neurohormonal status, which persists at LTFUP. A sustained reduction in the baseline PVC burden is associated with a lower risk of cardiac mortality, cardiac transplantation, or hospitalization for heart failure during follow-up. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Ablation of frequent premature ventricular complexes (PVCs) improves left ventricular ejection fraction in patients with left ventricular (LV) systolic dysfunction. This study aims to evaluate the long-term hard outcomes and potential prognostic variables in this population. METHODS AND RESULTS: Prospective multicentre study including 101 consecutive patients [56 ± 12 years old, 62 (61%) men] with LV systolic dysfunction and frequent PVCs who underwent PVC ablation before November 2015. The last evaluation performed was considered the long-term follow-up (LTFUP) evaluation. Mean follow-up was 34 ± 16 months (range 24-84 months). Ablation was successful in 95 (94%) patients. There was a significant reduction in the PVC burden from 21 ± 12% at baseline to 3.8 ± 6% at LTFUP, P < 0.001. Left ventricular ejection fraction improved from 32 ± 8% at baseline to 39 ± 12% at LTFUP (P < 0.001) and New York Heart Association class from 2.2 ± 0.6% to 1.3 ± 0.6% (P < 0.001). Brain natriuretic peptide levels decreased from 136 (78-321) to 68 (32-144) pg/mL (P = 0.007). Most of this improvement occurs during the first 6 months after ablation. Persistent abolition of at least 18 points of the baseline PVC burden was independently and inversely associated with the composite endpoint of cardiac mortality, cardiac transplantation, or hospitalization for heart failure during follow-up [hazard ratio 0.18 (0.05-0.66), P = 0.01]. CONCLUSION: In patients with LV systolic dysfunction, ablation of frequent PVCs induces a significant improvement in functional, structural, and neurohormonal status, which persists at LTFUP. A sustained reduction in the baseline PVC burden is associated with a lower risk of cardiac mortality, cardiac transplantation, or hospitalization for heart failure during follow-up. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Christian M Horvath; Christoph Fisser; T Douglas Bradley; John S Floras; Samuel Sossalla; Gianfranco Parati; Florian Zeman; Paolo Castiglioni; Andrea Faini; Fiona Rankin; Michael Arzt Journal: Int J Cardiol Heart Vasc Date: 2022-05-21
Authors: Pál Ábrahám; Mercédesz Ambrus; Szilvia Herczeg; Nándor Szegedi; Klaudia Vivien Nagy; Zoltán Salló; István Osztheimer; Gábor Széplaki; Tamás Tahin; Béla Merkely; László Gellér Journal: Europace Date: 2021-04-06 Impact factor: 5.214
Authors: Laia Yáñez-Bisbe; Anna Garcia-Elias; Marta Tajes; Isaac Almendros; Antonio Rodríguez-Sinovas; Javier Inserte; Marisol Ruiz-Meana; Ramón Farré; Núria Farré; Begoña Benito Journal: Int J Mol Sci Date: 2021-12-24 Impact factor: 5.923
Authors: Christoph Fisser; Lara Gall; Jannis Bureck; Victoria Vaas; Jörg Priefert; Sabine Fredersdorf; Florian Zeman; Dominik Linz; Holger Woehrle; Renaud Tamisier; Helmut Teschler; Martin R Cowie; Michael Arzt Journal: Front Cardiovasc Med Date: 2022-06-20
Authors: Christoph Fisser; Jannis Bureck; Lara Gall; Victoria Vaas; Jörg Priefert; Sabine Fredersdorf; Florian Zeman; Dominik Linz; Holger Wöhrle; Renaud Tamisier; Helmut Teschler; Martin R Cowie; Michael Arzt Journal: ERJ Open Res Date: 2021-08-02